HALOZYME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments
HALOZYME THERAPEUTICS, INC. (HALO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments · last filed 2017-02-28
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2016-03-31 was $0.00.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2015-12-31 was $0.00.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2015-09-30 was $0.00.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2016 was $0.00.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2015 was $0.00.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2014 was $0.00.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2013 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 | $0.00 derived: sum of 2 quarters · filed 2016-05-09 | $0.00 derived: sum of 3 quarters · filed 2016-05-09 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2015-03-02 | |||
| 2013-12-31 | $0.00 10-K · filed 2014-02-28 | |||
| 2012-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |